Literature DB >> 10668063

Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report.

W F Pirl1, A J Roth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10668063     DOI： 10.1002/(sici)1099-1611(200001/02)9:1<84::aid-pon440>3.0.co;2-t

Source DB:  PubMed          Journal:  Psychooncology        ISSN： 1057-9249            Impact factor:   3.894


× No keyword cloud information.
  18 in total

1.  Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.

Authors:  Sierra Vig; Laurel Seibert; Myke R Green
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-31       Impact factor: 4.553

Review 2.  Nausea and Vomiting in Advanced Cancer.

Authors:  Rudolph M Navari
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

3.  A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.

Authors:  Rudolph M Navari; Lawrence H Einhorn; Patrick J Loehrer; Steven D Passik; Jake Vinson; John McClean; Naveed Chowhan; Nasser H Hanna; Cynthia S Johnson
Journal:  Support Care Cancer       Date:  2007-03-21       Impact factor: 3.603

Review 4.  Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.

Authors:  Ting Yang; Qianxin Liu; Min Lu; Lingyue Ma; Ying Zhou; Yimin Cui
Journal:  Br J Clin Pharmacol       Date:  2017-03-23       Impact factor: 4.335

5.  A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.

Authors:  Rudolph M Navari; Lawrence H Einhorn; Steven D Passik; Patrick J Loehrer; Cynthia Johnson; M L Mayer; J McClean; Jake Vinson; W Pletcher
Journal:  Support Care Cancer       Date:  2005-02-08       Impact factor: 3.603

6.  The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Rudolph M Navari; Cindy K Nagy; Sarah E Gray
Journal:  Support Care Cancer       Date:  2013-01-12       Impact factor: 3.603

7.  Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.

Authors:  Zhonghan Zhang; Yaxiong Zhang; Gang Chen; Shaodong Hong; Yunpeng Yang; Wenfeng Fang; Fan Luo; Xi Chen; Yuxiang Ma; Yuanyuan Zhao; Jianhua Zhan; Cong Xue; Xue Hou; Ting Zhou; Shuxiang Ma; Fangfang Gao; Yan Huang; Likun Chen; Ningning Zhou; Hongyun Zhao; Li Zhang
Journal:  Oncologist       Date:  2018-01-12

Review 8.  Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.

Authors:  Ronald Chow; Leonard Chiu; Rudolph Navari; Steven Passik; Nicholas Chiu; Marko Popovic; Henry Lam; Mark Pasetka; Edward Chow; Carlo DeAngelis
Journal:  Support Care Cancer       Date:  2015-11-04       Impact factor: 3.603

Review 9.  Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

10.  Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.

Authors:  Florian Slimano; Florence Netzer; Isabelle Borget; François Lemare; Benjamin Besse
Journal:  Int J Clin Pharm       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.